Febrile Illness
26
5
6
16
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 26 trials
100.0%
+13.5% vs benchmark
12%
3 trials in Phase 3/4
31%
5 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (26)
Timmy3 Module Clinical Accuracy ISO 80601-2-56:2017 + A1 2018
A Rapid Triage Test to Improve Risk-stratification of Febrile Children (EChiLiBRiST, Clinical Trial 1, Outpatients)
Evaluation of Knowledge About Fever After Consultation in the Pediatric Emergency Department
Etiology of Febrile Illness in Nepal (DEFINe Study)
Knowledge, Attitudes, Perceptions and Behaviors of Healthcare Professionals and the General Population Regarding Vaccination During Febrile Illness
Village Malaria Worker Expansion
Febrile Illness in Kinshasa and Kimpese
Clinical Usefulness of a Multi-analyte Immunoassay for Distinguishing Bacterial and Viral Infections in Children
The Measurement of Vital Signs in Children by Lifelight® Software in Comparison to the Standard of Care
Incidences, Causes, and Outcomes of Febrile Illness in Rural South and Southeast Asia
Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Nigeria
Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Kenya
Febrile Illness in Guinea
NC Thermometer (Gen 3) ISO 80601-2-56 Validation
Prospective Study to Validate the Clinical Accuracy of Norbert Device to Measure Body Temperature
Health Itinerary of Young Children With Suspected Bloodstream Infection in Kisantu General Referral Hospital, DR Congo
Epidemiology and Clinical Characteristics of Emerging and Re-emerging Infectious Diseases With Epidemic Potential in Mali
Comparison of Thermometry in Canada for Pediatrics
Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: the TESTsmART Trial AIM 1
Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life